Core Insights - Harrow (HROW) reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.05, marking an earnings surprise of -140% [1] - The company generated revenues of $49.26 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 11.42%, but showing an increase from $34.27 million year-over-year [2] - Harrow's stock has increased by approximately 345.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 25.5% [3] Company Performance - Over the last four quarters, Harrow has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is $0.50 on revenues of $81.8 million, and for the current fiscal year, it is $0.09 on revenues of $223.66 million [7] - The estimate revisions trend for Harrow is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Drugs industry, to which Harrow belongs, is currently ranked in the top 25% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - The article emphasizes the importance of confirming the sustainability of a trend in short-term investing, highlighting that successful entry timing is crucial for capitalizing on price movements [1][2]. Group 1: Trend Analysis - The trend can reverse before exiting a trade, potentially leading to short-term capital losses for investors, necessitating confirmation of sound fundamentals and positive earnings estimates to maintain stock momentum [2]. - A unique short-term trading strategy, referred to as the "Recent Price Strength" screen, helps identify stocks with sufficient fundamental strength to sustain their recent uptrends [3]. Group 2: Stock Example - Harrow (HROW) - Harrow (HROW) has shown a solid price increase of 28.2% over the past 12 weeks, indicating investor confidence in its potential upside [4]. - HROW has maintained a price increase of 0.5% over the past four weeks, suggesting that the upward trend is still intact [5]. - Currently, HROW is trading at 82% of its 52-week high-low range, indicating a potential breakout opportunity [6]. Group 3: Fundamental Strength - HROW holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which are critical for near-term price movements [6]. - The stock also has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 4: Additional Opportunities - Besides HROW, there are several other stocks that meet the criteria of the "Recent Price Strength" screen, suggesting potential investment opportunities [8]. - The article encourages exploring over 45 Zacks Premium Screens tailored to different investing styles to identify winning stock picks [8].

The market expects Harrow (HROW) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on November 13, 2024, might help the stock move higher if these key numbers are ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 6th:Harrow, Inc. (HROW) : This eyecare pharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 164.3% over the last 60 days.Harrow’s shares gained 108.4% over the last three months compared with the S&P 500’s advance of 11.1%. The company possesses a Momentum Score  of B.Orla Mining Ltd. (ORLA) : This mining company has a Zac ...

Investors might want to bet on Harrow (HROW) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. The power of a c ...

Shares of Harrow (HROW) have gained 5% over the past four weeks to close the last trading session at $47.20, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $59.45 indicates a potential upside of 26%.The mean estimate comprises four short-term price targets with a standard deviation of $12.23. While the lowest estimate of $44.80 indicates a 5.1% decline from the current price le ...

Core Viewpoint - The article emphasizes the importance of identifying and maintaining trends in short-term investing, highlighting the utility of a "Recent Price Strength" screen to find stocks with strong fundamentals that can sustain upward momentum [1]. Group 1: Stock Performance - Harrow (HROW) has shown a significant price increase of 133.3% over the past 12 weeks, indicating strong investor interest [2]. - The stock has also maintained a price increase of 27% over the last four weeks, suggesting that the upward trend is still intact [2]. - HROW is currently trading at 94.6% of its 52-week high-low range, indicating a potential breakout [2]. Group 2: Fundamental Strength - HROW carries a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [3]. - The Zacks Rank system has a strong historical performance, with Rank 1 stocks averaging an annual return of +25% since 1988 [3]. - The Average Broker Recommendation for HROW is 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [3]. Group 3: Investment Strategy - The article suggests that HROW is not the only stock that meets the criteria of the "Recent Price Strength" screen, encouraging investors to explore other stocks that fit this profile [4]. - The article also mentions the availability of over 45 Zacks Premium Screens tailored to different investing styles, which can help identify potential winning stocks [4]. - The Zacks Research Wizard tool allows investors to backtest stock-picking strategies, enhancing the likelihood of successful investments [4].

Harrow (HROW) shares soared 8.4% in the last trading session to close at $49.75. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 16.8% gain over the past four weeks. Earlier this week, the company relaunched its ophthalmology drug, Triesence, which is approved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. This might have driven the sha ...

Stock Performance - Harrow Inc (HROW) shares increased by 3.26% during mid-day trading on October 2, reaching an intraday high of $46.10 before closing at $45.90, up from the previous close of $44.45 [1] - The current stock price is 3.47% below its 52-week high of $47.55 and 503.95% above its 52-week low of $7.60 [1] - Trading volume was recorded at 127,229 shares, which is 19.9% of the average daily volume of 640,221 shares [1] Analyst Forecasts - The average one-year price target for Harrow Inc (HROW) is $46.20, with a high estimate of $50.00 and a low estimate of $44.80, indicating a potential upside of 0.65% from the current price of $45.90 [2] - The consensus recommendation from four brokerage firms gives Harrow Inc an average rating of 1.8, suggesting an "Outperform" status on a scale where 1 is Strong Buy and 5 is Sell [2] - GuruFocus estimates the GF Value for Harrow Inc in one year to be $27.70, indicating a potential downside of 39.65% from the current price of $45.90 [2]

Financial Data and Key Metrics Changes - Harrow achieved record quarterly revenue of $48.9 million, representing a 46% increase year-over-year and a 42% increase quarter-over-quarter [5][6] - The company expects 2024 revenue to exceed $180 million, excluding contributions from TRIESENCE [6][12] Business Line Data and Key Metrics Changes - The Anterior Segment business saw revenue increase by over 40% compared to the first quarter of 2024 [5] - ImprimisRx compounding subsidiary achieved its highest quarterly revenue in history [5] - Branded revenue is now ahead of compounded revenue, positively impacting margins [6] Market Data and Key Metrics Changes - IHEEZO unit volumes nearly doubled, up about 98% from the previous quarter, with 24 supply agreements signed with strategic retina practice accounts [7] - VEVYE prescriptions increased by 212% from the first quarter of 2024, with a total of 3,000 prescribers [8][9] Company Strategy and Development Direction - The company aims to become North America's leading ophthalmic pharmaceutical company, focusing on expanding the VEVYE salesforce and opening new territories [12][11] - Harrow is actively pursuing Medicare coverage for VEVYE, with expectations for coverage to be in place by early 2025 [14][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational momentum and growth potential for the second half of 2024, particularly with the relaunch of TRIESENCE [6][12] - Positive feedback from physicians regarding VEVYE's effectiveness and tolerability was highlighted, indicating strong market demand [10][12] Other Important Information - The company has a strong market access strategy, with VEVYE currently exceeding internal goals, covering over 166 million lives [9] - The company is focused on maintaining profitability while expanding its market presence and product offerings [51] Q&A Session Summary Question: Can you provide commentary on Medicare coverage for VEVYE? - The company is in the process of attaining Medicare coverage, which is expected to take 18 to 24 months from the product launch [14] Question: What is the size and scope of the VEVYE sales force? - The VEVYE sales force currently covers only 36 out of 59 markets, with plans to expand coverage in the coming quarters [15][16] Question: Can you discuss the reorder activity for IHEEZO? - The reorder rate for IHEEZO is currently at 87%, indicating strong interest from physicians [49] Question: What is driving the success in the Medicaid market for VEVYE? - The market access team has been successful in securing Medicaid coverage with zero co-pay for patients in large markets like Texas and California [23][51] Question: What is the expected market opportunity for IHEEZO and VEVYE? - The market opportunity for IHEEZO is significant, with over 17 million annual use cases in the US, while VEVYE targets a large population suffering from moderate to severe dry eye disease [56]